Co-Administration of Combretastatin A4 Nanoparticles and Sorafenib for Systemic Therapy of Hepatocellular Carcinoma

2019 ◽  
Author(s):  
Yalin Wang ◽  
Haiyang Yu ◽  
Dawei Zhang ◽  
Guanyi Wang ◽  
Wantong Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Combretastatin A4

Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma

2019 ◽  
Vol 92 ◽  
pp. 229-240 ◽  
Author(s):  
Yalin Wang ◽  
Haiyang Yu ◽  
Dawei Zhang ◽  
Guanyi Wang ◽  
Wantong Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Combretastatin A4

Systemic therapy of hepatocellular carcinoma: Are we making progress?

2008 ◽  
Vol 25 (11) ◽  
pp. 1089-1104 ◽  
Author(s):  
Patricia Roxburgh ◽  
T. R. Jeffry Evans
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy

scholarly journals Systemic therapy for hepatocellular carcinoma: why do we keep failing?

2014 ◽  
Vol 1 (4) ◽  
pp. 355-358
Author(s):  
Bo Hyun Kim ◽  
Joong-Won Park
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy

Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib

2022 ◽  
Vol 11 (3) ◽  
pp. 45-52
Author(s):  
V.  V. Breder ◽  
D.  T. Abdurakhmanov ◽  
V.  V. Petkau ◽  
P.  V. Balakhnin ◽  
M.  V. Volkonsky ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Therapy ◽  
Liver Function ◽  
Real World ◽  
Systemic Therapy ◽  
Efficacy And Safety ◽  
Study Results ◽  
Class B ◽  
Pugh Class ◽  
Positive Results

There is a number of unresolved issues regarding the systemic therapy administration for hepatocellular carcinoma (HCC). Their solution is facilitated by accumulating real‑world study results. Lenvatinib therapy is a recognized drug with a good efficacy and safety profile for the treatment of HCC. Subanalyses of the REFLECT study showed that the absence of stratification by baseline AFP and baseline liver function, as well as the lack of options for subsequent drug therapy after lenvatinib, also affects the outcomes. Once these factors are taken into account, the hypothesis of superiority of lenvatinib to sorafenib and other drugs can be tested. Real‑world clinical studies have demonstrated positive results of lenvatinib therapy in patients with Child‑Pugh class B liver function, provided recommendations on the sequence of systemic therapy after lenvatinib and on the use of lenvatinib in patients with BCLC stage B, along with considering the possibility of lenvatinib monotherapy and the prospects for its use in patients with nHCC. Further real‑world studies of lenvatinib for HCC in the Russian population are required.

Predictive biomarkers for systemic therapy of hepatocellular carcinoma

2021 ◽  
Author(s):  
Nurbubu T. Moldogazieva ◽  
Sergey P. Zavadskiy ◽  
Susanna S. Sologova ◽  
Innokenty M. Mokhosoev ◽  
Alexander A. Terentiev
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Predictive Biomarkers

scholarly journals Evolution of systemic therapy of advanced hepatocellular carcinoma

2008 ◽  
Vol 14 (42) ◽  
pp. 6546 ◽  
Author(s):  
Ming Jiang ◽  
Fei Liu ◽  
Wu-Jun Xiong ◽  
Lan Zhong ◽  
Xi-Mei Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Advanced Hepatocellular Carcinoma

scholarly journals Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib

2015 ◽  
Vol 1 (2) ◽  
pp. 58 ◽  
Author(s):  
Lombardi Giuseppe ◽  
Sara Lonardi ◽  
Bellu Luisa ◽  
Pambuku Ardi ◽  
Marsico Valentina ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Elderly Patients ◽  
Systemic Therapy ◽  
Concise Review
Sign in / Sign up

Export Citation Format

Share Document